GITNUX MARKETDATA REPORT 2024

Biosimilars Industry Statistics

The biosimilars industry is expected to continue growing rapidly, driven by increasing demand for cost-effective alternatives to biologic drugs.

Statistic 1

"Biosimilar patents for major drug companies like Roche and AbbVie are set to expire, opening the market to competition."

Sources Icon

Statistic 2

"The market is expected to grow at a compound annual growth rate (CAGR) of 24.7% from 2022 to 2029."

Sources Icon

Statistic 3

"By 2023, around 10 blockbuster biologics, including Humira, are expected to face biosimilar competition."

Sources Icon

Statistic 4

"South Korea's Celltrion is one of the leading companies in the global biosimilars market."

Sources Icon

Statistic 5

"The biosimilars market in Asia-Pacific is expected to grow significantly, driven by lower manufacturing costs."

Sources Icon

Statistic 6

"Biosimilars have the potential to reduce healthcare costs by an estimated $54 billion over 10 years."

Sources Icon

Statistic 7

"Europe accounted for the largest market share, with around 40% of the global biosimilars market in 2021."

Sources Icon

Statistic 8

"The price of biosimilars is typically 15% to 35% lower than their reference biologics."

Sources Icon

Statistic 9

"By the end of 2021, biosimilars represented about 2% of the total biologics market."

Sources Icon

Statistic 10

"76% of healthcare providers in a U.S. survey expressed confidence in prescribing biosimilars."

Sources Icon

Statistic 11

"The total hospital savings from biosimilars in the EU was estimated at €1.6 billion in 2021."

Sources Icon

Statistic 12

"The United States biosimilars market is expected to grow at a CAGR of 25% from 2022 to 2027."

Sources Icon

Statistic 13

"The monoclonal antibodies segment holds the largest market share in the biosimilars market."

Sources Icon

Statistic 14

"As of 2021, there were 29 biosimilars approved by the FDA in the United States."

Sources Icon

Statistic 15

"Germany is the leading market in Europe for biosimilars."

Sources Icon

Statistic 16

"The first biosimilar approved in the U.S. was Zarxio, in 2015."

Sources Icon

Statistic 17

"Biosimilar infliximab (Remicade) has been one of the most successful biosimilars, saving $4.5 billion in the EU."

Sources Icon

Statistic 18

"Biosimilars could potentially create savings of $100 billion to $150 billion over the next decade in the U.S."

Sources Icon

Statistic 19

"The global biosimilars market was valued at approximately $19.12 billion in 2021."

Sources Icon

Statistic 20

"The oncology segment is expected to be the fastest-growing segment in the biosimilars market."

Sources Icon

... Before You Leave, Catch This! 🔥

Your next business insight is just a subscription away. Our newsletter The Week in Data delivers the freshest statistics and trends directly to you. Stay informed, stay ahead—subscribe now.

Sign up for our newsletter and become the navigator of tomorrow's trends. Equip your strategy with unparalleled insights!